Posters

      A mechanistic study of cigarette smoke-induced COPD in C57BL/6 mice: The changes in lung epigenome following smoking cessation or switching to aerosol from a prototypic modified risk tobacco product

      Sierro, N.; Talikka, M.; Hoeng, J.; Peitsch, M. C.; Hayes, A. W.; Ivanov, N. V.

      Conference date
      Mar 23, 2015
      Conference name
      Society of Toxicology (SOT) 2015
      Link to more information
      Topic
      Summary

      Introduction: Chronic Obstructive Pulmonary Disease (COPD) is the major cause of chronic morbidity and mortality in the world. It is defined as progressive, irreversible airflow limitation caused by the combined effects of emphysema, chronic bronchitis, and narrowing of the small airways. In the western world cigarette smoke is the main etiological factor in the pathogenesis of COPD. Even though aberrant histone modifications have been the focus of epigenetic studies around COPD, some studies have indicated that DNA methylation might also play a role in the COPD pathology. p16 and GATA4 methylation has been associated with lower percent predicted FEV1 in sputum. A larger scale analysis from white blood cells proposed DNA methylation as a possible biomarker of COPD. 70% of the identified 349 methylated CpG sites were outside of CpG islands and significantly associated with COPD severity. In addition to the predictive value, such methylation patterns may identify new molecular pathways involved in COPD pathogenesis. Known mechanisms by which cigarette smoke modulates DNA methylation have been reviewed by Lee and Pausova.  

      Related Publications

      The biological effects of long-term exposure of human bronchial epithelial cells to total particulate matter from a candidate modified-risk tobacco product

      Aerosol Chemistry Pre-clinical Toxicology Systems Toxicology

      Systems toxicology assessment of the biological impact of a candidate Modified Risk Tobacco Product on human organotypic oral epithelial cultures

      Aerosol Chemistry Pre-clinical Toxicology Systems Toxicology

      Systems toxicology-based assessment of the candidate modified risk tobacco product THS2.2 for the adhesion of monocytic cells to human coronary arterial endothelial cells

      Aerosol Chemistry Pre-clinical Toxicology Systems Toxicology

      Toxicity of aerosols of nicotine and pyruvic acid (separate and combined) in Sprague–Dawley rats in a 28-day OECD 412 inhalation study and assessment of systems toxicology

      Aerosol Chemistry Pre-clinical Toxicology Systems Toxicology

      Cigarette smoke induces molecular responses in respiratory tissues of ApoE−/− mice that are progressively deactivated upon cessation

      Aerosol Chemistry Pre-clinical Toxicology Systems Toxicology

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.